Business
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL®
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S.CLEAR Outcomes Study Design Highlighted in The American Heart Journal and Progresses Uninterrupted Despite PandemicConference Call and Webcast Today, February 23rd at 4:30 P.M. Eastern Time ANN ARBOR, Mich., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. “Even though 2020 was an exceptionally challenging year, we made progress in our mission of Lipid Management for Everyone. Successes include the U.S. FDA approval of NEXLETOL® and NEXLIZET®, our innovative oral, once-daily, non-statin LDL-C lowering medicines for indicated patients, the EU EMA approval of NILEMDO® and NUSTENDI® and the first-ever EU product royalty revenue from Daiichi Sankyo Europe, establishing a collaboration with another world-class partner for our medicines in Japan and making uninterrupted progress on our landmark CLEAR Outcomes trial in statin intolerant patients, all while battling the headwinds of the COVID-19 pandemic,” said Tim M. Mayleben, president and chief executive officer of ESPERION. “While navigating the unprecedented environment, we adjusted our commercial and operational footprint, while also optimizing our cost structure to position our team to realize the full potential of our medicines as the negative impact of the pandemic recedes. I am very optimistic for our future growth prospects.” 2020 Key Accomplishments and Recent Highlights Achieved U.S. FDA approval for NEXLETOL® and NEXLIZET®, the first ever non-statin fixed-dose combination medicine for LDL-C loweringSecured EU approval of NILEMDO® and NUSTENDI® in Europe and transferred marketing authorizations to Daiichi Sankyo Europe (DSE)Reported first royalty revenue from DSE following initial European launch of NILEMDO® and NUSTENDI® in Germany during November, reaching 4,000 patients by year endEntered development and commercialization agreement with Otsuka Pharmaceutical in JapanAccumulated over 50% of the 4-component MACE primary endpoints in the CLEAR Outcomes Study which has 14,000 stat...